NasdaqGS:ADXS

Stock Analysis Report

Executive Summary

Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Share Price & News

How has Advaxis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-22.7%

ADXS

3.8%

US Biotechs

2.3%

US Market


1 Year Return

-96.9%

ADXS

-10.0%

US Biotechs

5.6%

US Market

Return vs Industry: ADXS underperformed the US Biotechs industry which returned -10% over the past year.

Return vs Market: ADXS underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

ADXSIndustryMarket
7 Day-22.7%3.8%2.3%
30 Day5.1%-2.8%-1.0%
90 Day-74.6%-2.6%-0.7%
1 Year-96.9%-96.9%-9.2%-10.0%7.9%5.6%
3 Year-99.8%-99.8%14.7%10.7%45.6%36.3%
5 Year-99.3%-99.3%2.2%-2.8%65.8%47.6%

Price Volatility Vs. Market

How volatile is Advaxis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Advaxis undervalued compared to its fair value and its price relative to the market?

0.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate ADXS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ADXS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ADXS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ADXS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ADXS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADXS is good value based on its PB Ratio (0.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Advaxis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-23.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADXS's revenue is expected to decline over the next 3 years (-47.2% per year).

High Growth Revenue: ADXS's revenue is forecast to decline over the next 3 years (-47.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if ADXS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Advaxis performed over the past 5 years?

-11.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ADXS is unprofitable, and losses have increased over the past 5 years at a rate of -11.6% per year.

Accelerating Growth: Unable to compare ADXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADXS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: ADXS has a negative Return on Equity (-50.79%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ADXS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ADXS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Advaxis's financial position?


Financial Position Analysis

Short Term Liabilities: ADXS's short term assets ($45.5M) exceeds its short term liabilities ($5.7M)

Long Term Liabilities: ADXS's short term assets (45.5M) exceeds its long term liabilities (1.2M)


Debt to Equity History and Analysis

Debt Level: ADXS is debt free.

Reducing Debt: ADXS has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.


Balance Sheet

Inventory Level: ADXS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ADXS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADXS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ADXS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -20.3% each year


Next Steps

Dividend

What is Advaxis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ADXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ADXS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ADXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADXS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADXS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Advaxis's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Ken Berlin (55yo)

1.5yrs

Tenure

US$1,797,456

Compensation

Mr. Kenneth A. Berlin, also known as Ken, J.D., serves as President, Chief Executive Officer and Director of Advaxis, Inc. since April 23, 2018. He served as the Chief Executive Officer and President of Ro ...


CEO Compensation Analysis

Compensation vs. Market: Ken has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Ken's compensation with company performance.


Management Age and Tenure

1.5yrs

Average Tenure

58yo

Average Age

Experienced Management: ADXS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

4.7yrs

Average Tenure

59yo

Average Age

Experienced Board: ADXS's board of directors are considered experienced (4.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$11,39111 Apr 19
Roni Appel
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,000
Max PriceUS$3.80
SellUS$2,29907 Nov 18
Robert Petit
EntityIndividual
Role
Chairman of Advisory Board
Chairman of Scientific Advisory Board
Shares264.2
Max PriceUS$8.70
SellUS$4,75505 Nov 18
Robert Petit
EntityIndividual
Role
Chairman of Advisory Board
Chairman of Scientific Advisory Board
Shares566.07
Max PriceUS$8.40

Ownership Breakdown


Management Team

  • Tony Lombardo (70yo)

    Executive Officer

    • Tenure: 1.5yrs
    • Compensation: US$967.80k
  • Molly Henderson (48yo)

    Executive VP

    • Tenure: 1.3yrs
    • Compensation: US$521.87k
  • Andres Gutierrez (58yo)

    Executive VP & Chief Medical Officer

    • Tenure: 1.5yrs
  • Ken Berlin (55yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$1.80m
  • Robert Petit (59yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0.3yrs
    • Compensation: US$730.69k
  • Ranya Dajani

    Vice President of Business Development

    • Tenure: 2.8yrs

Board Members

  • Richard Berman (76yo)

    Independent Director

    • Tenure: 14.1yrs
    • Compensation: US$141.60k
  • Roni Appel (52yo)

    Independent Director

    • Tenure: 14.9yrs
    • Compensation: US$122.50k
  • Jim Patton (61yo)

    Independent Vice Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$189.25k
  • David Sidransky (59yo)

    Chairman

    • Tenure: 4.4yrs
    • Compensation: US$203.55k
  • Jedd Wolchok

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Toni Ribas

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Ken Berlin (55yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$1.80m
  • Robert Petit (59yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0.3yrs
    • Compensation: US$730.69k
  • Samir Khleif (55yo)

    Independent Director

    • Tenure: 5yrs
    • Compensation: US$130.00k
  • Nancy Freitag

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Advaxis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advaxis, Inc.
  • Ticker: ADXS
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.734m
  • Shares outstanding: 24.71m
  • Website: https://www.advaxis.com

Number of Employees


Location

  • Advaxis, Inc.
  • 305 College Road East
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADXSNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJul 2005
FAD2DB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2005

Biography

Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:52
End of Day Share Price2019/10/16 00:00
Earnings2019/07/31
Annual Earnings2018/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.